Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
Condition(s):HER2-negative Breast CancerLast Updated:March 6, 2023Recruiting
Include Studies Not Open or Pending
Condition(s):HER2-negative Breast CancerLast Updated:March 6, 2023Recruiting
Condition(s):Fecal Microbiota Transplantation; Clostridium Difficile Infection; Gut MicrobiomeLast Updated:January 31, 2024Recruiting
Condition(s):Stroke; Patent Foramen OvaleLast Updated:March 19, 2024Recruiting
Condition(s):Primary Biliary CirrhosisLast Updated:February 15, 2024Recruiting
Condition(s):Degenerative OsteoarthritisLast Updated:January 16, 2024Recruiting
Condition(s):Grade II Meningioma; Intracranial MeningiomaLast Updated:February 7, 2024Recruiting
Condition(s):Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia MyelofibrosisLast Updated:February 20, 2024Recruiting
Condition(s):Non-Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Any Solid TumorLast Updated:March 4, 2024Recruiting
Condition(s):Prostate CancerLast Updated:May 6, 2023Recruiting
Condition(s):Spinal Cord InjuryLast Updated:September 24, 2020Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.